Ventyx Biosciences Inc (VTYX)
4.805
-0.18
(-3.51%)
USD |
NASDAQ |
May 20, 16:00
4.805
0.00 (0.00%)
After-Hours: 17:27
Ventyx Biosciences SG&A Expense (Quarterly): 8.021M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.021M |
| December 31, 2023 | 8.326M |
| September 30, 2023 | 8.201M |
| June 30, 2023 | 8.585M |
| March 31, 2023 | 7.115M |
| December 31, 2022 | 8.386M |
| September 30, 2022 | 5.952M |
| June 30, 2022 | 5.722M |
| Date | Value |
|---|---|
| March 31, 2022 | 5.338M |
| December 31, 2021 | 4.002M |
| September 30, 2021 | 2.242M |
| June 30, 2021 | 1.675M |
| March 31, 2021 | 0.747M |
| December 31, 2020 | 0.133M |
| September 30, 2020 | 0.245M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.133M
Minimum
Dec 2020
8.585M
Maximum
Jun 2023
4.979M
Average
5.722M
Median
Jun 2022
SG&A Expense (Quarterly) Benchmarks
| Anavex Life Sciences Corp | 2.79M |
| CERo Therapeutics Holdings Inc | -- |
| Avinger Inc | 3.837M |
| Checkpoint Therapeutics Inc | 2.451M |
| RAPT Therapeutics Inc | 7.737M |